Business
Spectral AI Adds Additional Clinical Sites to Multi-Center Diabetic Foot Ulcer (DFU) Study
DALLAS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company
About this update from Spectral Ai, Inc.
[{"type":"text","content":"DALLAS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the addition of seven clinical sites that are currently enrolling to support the development of its diabetic foot ulcer (DFU) application for the DeepView® Wound Imaging System. The proprietary technology combines multi-spectral imaging and AI technology to provide clinicians with an immediate healing assessment of DFU’s for more accurate and timely diagnosis and therapeutic intervention. Participating investigators and clinical sites include: Dr. Tony Alleman, MD, University of Tennessee Health Science CenterDr. Ian Barron, DPM, Gentle Foot Care Hilliard and Gentle Foot Care Grove CityDr. Stephen Frania, DPM, Foot and Ankle Specialist of OhioDr. Vladimir Zeetser, DPM, Premium Podiatry and Wound CareDr. Charles Ananian, DPM, New Hope Podiatry GroupDr. Karl Fulkert, DPM, Worthington Foot and Ankle “We are pleased to announce the addition of seven additional clinical sites that will provide valuable data for Spectral AI’s DeepView® AI algorithm development,” said Mary Regan, PhD, VP of Clinical Affairs at Spectral AI. “We have selected leading wound care providers for these sites as we have done in the past. I look forward to advancing our DeepView® Wound Imaging technology and acquiring high quality data for this study.” The data collected from these additional sites will be incorporated to bolster the database for the development of the DFU healing prediction algorithm using the Company's DeepView® technology and support the Company’s applications for FDA, UKCA, and CE mark approval for DeepView®’s DFU indication. “The potential integration of AI imaging technology into our medical practice represents an advancement in patient care,” said Brian Inkrott, Founding Partner of Statera. “This cutting-edge tool could enable us to quickly diagnose and monitor wound healing with greater accuracy and efficiency, paving the way for tailoring treatments more precisely to each patient's needs.” DFU is a severe chronic diabetic complication that consists of lesions in the deep tissues associated with neurological disorders and peripheral vascular disease in the lower limbs. It is...